特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
232775

ホジキンリンパ腫:パイプライン分析

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 880 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
ホジキンリンパ腫:パイプライン分析
出版日: 2020年02月28日
発行: Global Markets Direct
ページ情報: 英文 880 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ホジキンリンパ腫とはリンパ系組織のがんの一種で、リンパ節や脾臓、肝臓、骨髄などの箇所に現れます。患者の年齢層は15~30歳、または50~70歳が大半を占めています。一部の症例では、エプスタイン=バー・ウイルス(EBV)への感染歴が発症につながっていると考えられています。また、HIV感染歴のある場合も一般人より発症リスクが高くなっています。主な症状として、頚部・腋下・鼠径部のリンパ節の痛みを伴わない腫脹や、発熱・悪寒、寝汗、体重減少、食欲減退、皮膚の痒みなどが挙げられます。主な治療法には、外科手術や放射線治療、化学療法などがあります。

当レポートでは、世界各国でのホジキンリンパ腫治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

ホジキンリンパ腫の概要

治療薬の開発

  • ホジキンリンパ腫向けパイプライン製品:概要
  • ホジキンリンパ腫向けパイプライン製品:比較分析

各企業で開発中のホジキンリンパ腫治療薬

大学/研究機関で研究中のホジキンリンパ腫治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

ホジキンリンパ腫治療薬:開発中の製品の一覧(企業別)

ホジキンリンパ腫治療薬:研究中の製品の一覧(大学/研究機関別)

ホジキンリンパ腫治療薬の開発に従事している企業

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.
  • ADC Therapeutics Sarl
  • Affimed Therapeutics AG
  • Arbutus Biopharma Corporation
  • Bellicum Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cell Medica Limited
  • Cellular Biomedicine Group, Inc.
  • Constellation Pharmaceuticals, Inc.
  • Curis, Inc.
  • Faron Pharmaceuticals Oy
  • Fate Therapeutics, Inc.
  • Gamida Cell Ltd.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Mirati Therapeutics Inc.
  • Molecular Templates Inc.
  • NantKwest, Inc.
  • Novartis AG
  • 小野薬品工業
  • Pfizer Inc.
  • Pharmacyclics, Inc.
  • Philogen S.p.A.
  • Rich Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Selvita S.A.
  • Sigma-Tau S.p.A.
  • Spectrum Pharmaceuticals, Inc.
  • Stemline Therapeutics, Inc.
  • Syndax Pharmaceuticals, Inc.
  • 武田薬品工業
  • TG Therapeutics, Inc.
  • Theravectys SA
  • Trillium Therapeutics Inc.

ホジキンリンパ腫:治療薬の評価

  • 単剤治療薬の場合
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (INCB-039110 + INCB-040093)
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • abexinostat hydrochloride
  • acalisib
  • ADCT-301
  • AFM-13
  • Alocrest
  • aNK Program
  • azacitidine
  • BMS-986016
  • BPX-501
  • ブレンツキシマブベドチン
  • CBM-C30.1
  • ホジキン・非ホジキンリンパ腫向け細胞免疫療法
  • 腫瘍学向け細胞免疫療法
  • ホジキン・非ホジキンリンパ腫向け CD30標的細胞免疫療法
  • ホジキンリンパ腫・慢性リンパ性白血病向けGM-CSF標的細胞免疫療法
  • EBウイルス関連腫瘍・感染症向けLMP/BARF-1/EBNA1標的細胞免疫療法
  • 腫瘍学・感染症疾患向けLMP-1/LMP-2標的細胞免疫療法
  • 腫瘍学・滑膜肉腫X向けNY-ESO-1/MAGEA4/PRAME/スルビビン標的細胞免疫療法
  • CMD-003
  • CPI-0610
  • CUDC-907
  • entinostat
  • エプスタイン・バー(EB)・ウイルス・ワクチン
  • Ferritarg
  • FP-1304
  • FT-1050
  • haNK Program
  • INCB-40093
  • Indimitecan
  • Indotecan hydrochloride
  • Iomab-B
  • ipilimumab
  • ixazomib citrate
  • lirilumab
  • MK-2206
  • mocetinostat
  • 血液系腫瘍向けPD-1/PD-L1阻害モノクローナル抗体
  • 腫瘍学向けCD45標的モノクローナル抗体複合体
  • NiCord
  • nivolumab
  • NSC-678515
  • パノビノスタット
  • ペンブロリズマブ
  • PF-06801591
  • PNK-007
  • 塩酸プロカルバジン
  • radretumab
  • 黒色腫・ホジキンリンパ腫向け組換タンパク質
  • resminostat
  • ricolinostat
  • RP-323
  • ruxolitinib phosphate
  • SEL-24B489
  • SL-101
  • SL-501
  • temsirolimus
  • TGR-1202
  • TKM-PLK1
  • TTI-621
  • 鼻咽腔癌・ホジキンリンパ腫向けワクチン

ホジキンリンパ腫治療薬:パイプライン製品の最新動向

ホジキンリンパ腫治療薬:開発が休止状態の製品

ホジキンリンパ腫治療薬:開発が中止された製品

ホジキンリンパ腫関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース
  • ■付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics SA, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Agios Pharmaceuticals Inc, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12009IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Pipeline Review, H1 2020, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 1, 42, 40, 1, 15, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 6, 2, 1, 3 and 1 molecules, respectively.

Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

TABLE OF CONTENTS

Introduction

  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug Profiles
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.